AVADEL PHARMACEUTICALS PLC 4

Director Mark Anthony McCamish tendered 89,025 Avadel ordinary shares at $21.00 per share and had 291,000 stock options cashed out and canceled in connection with the Alkermes acquisition, exiting his equity position.

On February 12, 2026, Mark Anthony McCamish disposed of all his Avadel Pharmaceuticals plc ordinary shares and stock options in connection with the cash acquisition of Avadel by Alkermes plc under a court-approved scheme of arrangement. Each ordinary share, including those previously subject to vesting restrictions, was converted into $21.00 in cash plus a contingent value right (CVR) for a potential additional $1.50 per share upon milestone achievement, resulting in a cash payout of approximately $1.86 million for 89,025 shares held directly and via the McCamish Charitable Remainder Trust. Concurrently, all outstanding options covering an aggregate of 291,000 shares with exercise prices ranging from $4.79 to $16.32 were canceled and converted into cash equal to the intrinsic value based on the $21.00 deal price plus corresponding CVRs, leaving the reporting person with no remaining Avadel equity holdings after the merger close.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

4

Source Type

sec

Accession

0001104659-26-014444

Alert Tier

6